The Pershing Square founder smartly used a cleverly disguised subsidiary to build up its largest investment ever, in Botox-maker Allergan. It has similar plans for the future, although the element of surprise may have been lost. Read more »
Bill Ackman is pretty good at waiting. He waited more than a year for JC Penney to see the light and hire the guy he wanted as CEO, and then another year-and-a-half for that guy to fail spectacularly and saddle him with a half-billion dollar loss. Speaking of half-billion dollar losses, he waited for more than a year for a power that is to start looking into his allegation that there’s something amiss at diet-shake distributor and distributor-recruiter Herbalife, and now he’s patiently waiting for one of them to shut it down.
So he’s happy to wait for a couple of months while the people who make Botox consider their options while protected by a poison pill. Just as long as the option they come down on is selling their company for $46 billion to his chosen buyer, or to someone else for a bunch more. Read more »
Ackman, who has teamed up with Canadian pharmaceutical company Valeant to launch a $45.6 billion takeover of Botox maker Allergan, warned drugmakers Tuesday that he plans to go on a little buying spree. “This is not the last deal we’re going to do,” he said. “We’re already talking about the next deal we’re going to do with Valeant.” “There are $10 trillion worth of targets,” said Ackman, referring to the combined market cap of the pharmaceutical industry. “I call this the shopping list.” [NYP]
Every Ackman investment appears to have made money this year, including Beam, the Herbalife short and Platform Specialty Products Corp. Nutritional supplement maker Herbalife, for example, has been hit by reports of several government investigations into the company, which has helped push the stock down about 26 percent so far in 2014. The Pershing Square International fund is up 11.1 percent net of fees in the first quarter alone, according to a report by the HSBC Alternative Investment Group. [NetNet]
This week was looking like one that Bill Ackman would want to forget. It began with a New York Times article that read like something Herbalife CEO Michael Johnson and Carl Icahn might have collaborated on. It continued with yesterday’s $300 million Fannie Mae/Freddie Mac hiccup. Even Ackman’s latest presentation on what he very sincerely hopes is a pyramid scheme, accusing Herbalife of breaking Chinese laws, failed to either lift his spirit or dent its stock price. But this has definitely accomplished the latter, and almost certainly the former. Read more »